Kinases can phosphorylate and regulate androgen receptor activity during prostate cancer progression. In particular, we showed that glycogen synthase kinase-3␤ phosphorylates the androgen receptor, thereby inhibiting androgen receptor-driven transcription. Conversely, the glycogen synthase kinase-3␤ inhibitor lithium chloride suppressed the glycogen synthase kinase-3␤-mediated phosphorylation of the androgen receptor, thereby enabling androgen receptor-driven transcription to occur. The androgen receptor hinge and ligandbinding domains were important for both the phosphorylation and the inhibition of transcriptional activity of the receptor by glycogen synthase kinase-3␤. Furthermore, androgen receptor phosphorylation was augmented by LY294002, an indirect inhibitor of protein kinase B/Akt that inhibits glycogen synthase kinase-3␤. We also showed that the mutation of various phosphorylation sites on glycogen synthase kinase-3␤ affected the ability of these mutants to co-distribute with the androgen receptor in the cell nucleus, also that both glycogen synthase kinase-3␤ and androgen receptor proteins can be found in cell nuclei of prostate cancer tissue samples. Because glycogen synthase kinase-3␤ activity is suppressed after the enzyme is phosphorylated by protein kinase B/Akt and Akt activity frequently increases during the progression of prostate cancer, nullification of the glycogen synthase kinase-3␤-mediated suppression of androgen receptor activity by Akt likely contributes to prostate cancer progression.
Kinases can phosphorylate and regulate androgen receptor activity during prostate cancer progression. In particular, we showed that glycogen synthase kinase-3␤ phosphorylates the androgen receptor, thereby inhibiting androgen receptor-driven transcription. Conversely, the glycogen synthase kinase-3␤ inhibitor lithium chloride suppressed the glycogen synthase kinase-3␤-mediated phosphorylation of the androgen receptor, thereby enabling androgen receptor-driven transcription to occur. The androgen receptor hinge and ligandbinding domains were important for both the phosphorylation and the inhibition of transcriptional activity of the receptor by glycogen synthase kinase-3␤. Furthermore, androgen receptor phosphorylation was augmented by LY294002, an indirect inhibitor of protein kinase B/Akt that inhibits glycogen synthase kinase-3␤. We also showed that the mutation of various phosphorylation sites on glycogen synthase kinase-3␤ affected the ability of these mutants to co-distribute with the androgen receptor in the cell nucleus, also that both glycogen synthase kinase-3␤ and androgen receptor proteins can be found in cell nuclei of prostate cancer tissue samples. Because glycogen synthase kinase-3␤ activity is suppressed after the enzyme is phosphorylated by protein kinase B/Akt and Akt activity frequently increases during the progression of prostate cancer, nullification of the glycogen synthase kinase-3␤-mediated suppression of androgen receptor activity by Akt likely contributes to prostate cancer progression.
Androgens and androgen receptors (ARs), 1 which like other steroid nuclear receptors, can be regulated by kinases (1) (2) (3) (4) (5) . In the prostate, AR helps maintain the balance between the growth and death of prostate cells (4) . Structurally, the AR has a transactivation domain (amino acids 1-556), a DNA-binding domain (amino acids 559 -627), a hinge region (amino acids 622-670), and a ligand-binding domain (amino acids 712-919) (3) . During the progression of prostate cancer, however, ARs can become mutated or their regulation compromised, which often leads to the development of androgen-independent prostate cancer (4, 6) . Androgen-independent prostate cancer is a lethal recurring tumor that often develops in patients who have undergone androgen ablation therapy. Multiple factors can cause androgen-independent prostate cancer (4), but the most common factor, and the one that helps drive both normal and dysfunctional receptor activity, is the phosphorylation of AR.
Data suggest that kinases regulate AR function, but which kinases are involved remains unresolved. Rigorous phosphoamino acid analyses of the AR have shown that serine phosphorylation events are more prevalent than either threonine or tyrosine suggesting that serine kinases may exert most of the influence on the AR (1, 7) . Many consensus sites are present in the AR for serine kinases including mitogen-activated protein kinases, calmodulin-dependent protein kinases, and glycogen synthase kinase (GSK)-3 (8) . In one instance, Ser 308 in the AR was identified as a phosphorylation site but the kinase that phosphorylates it remains to be identified (9) . Others have shown that serines 81 and 94 become phosphorylated soon after translation and when these sites are mutated this limits ligand-induced phosphorylation but not transactivation (7, 10) . Also, the mutation of serine 650 reduces transcriptional regulation of an androgen response element (ARE) containing promoter construct by 30% (10) . The importance of Akt kinase activity in prostate cancer has been well documented (11) (12) (13) (14) (15) , particularly the direct involvement of Akt in phosphorylating AR. For example, one study showed that the phosphorylation of AR on Ser 210 and Ser 790 by Akt stimulated AR-driven transcriptional activity (16) , whereas another study showed that Akt suppressed activity (17) . However, both of these studies using in vitro kinase assays in combination with site-directed mutagenesis, putatively showed FIG. 1. Changes in the phosphorylation state of GSK-3␤ alter its ability to phosphorylate the AR. A, Western blot analysis was performed to compare the phosphorylation status of GSK-3␤ in AR-deficient (ARϪ) (PC-3, DU145, and C3) and AR-expressing cells (ARϩ) (LNCaP, A103, and V28) prostatic carcinoma cells. The total levels of GSK-3␤ were similar in all cell types (bottom row), and there was little difference in the (P)Tyr 216 -GSK-3␤ levels (middle row). The (P)Ser 9 -GSK-3␤ level was higher in the ARϩ cells, LNCaP, compared with ARϪ cells, PC-3, DU145, that Ser 213 and Ser 791 were the amino acids on AR that were phosphorylated by Akt. Limited in vivo analysis further indicated that Akt mediated the phosphorylation of AR in COS-1 cells, but no attempt was made to determine whether Akt and AR were co-localized within cells (17) . In contrast with these findings, other studies by Gioeli et al. (18) 213 and Ser 791 on AR and the failure to confirm in vivo that these sites are phosphorylated led us to postulate that GSK-3␤ regulates AR as an indirect consequence of Akt activity. GSK-3␤ is a likely candidate for regulating AR as an indirect mediator of Akt activity for multiple reasons. One reason is that GSK-3␤ is known to phosphorylate and mediate the activity of numerous nuclear transcription factors (19) ; another is that GSK-3␤ is inactivated after being phosphorylated on Ser 9 by Akt (19, 20) . We have recently shown that GSK-3␤ can phosphorylate cyclic AMP response element-binding protein and activate its transcriptional activity in the nuclei of PC-3 prostate carcinoma cells (21) . In the present study, we used prostate carcinoma cells and COS-1 cells to: 1) examine the phosphorylation of AR by GSK-3␤ and its effects on AR-mediated transcription; 2) determine the AR protein domain that in-FIG. 2. Activated GSK-3␤ and AR distribution in prostate cells. We examined the localization of AR (blue) and GSK-3␤ (green) in R1881-treated prostate cancer cells after counterstaining samples for actin (red). In C3 cells stably expressing an empty transfection vector, no AR was observed (asterisk). The intracellular distribution of GSK-3␤ (green) in C3 cells varied with the variant that was transfected into cells. The GSK-3␤wt was distributed in both the nucleus and cytoplasm of C3 cells, whereas the GSK-3␤
⌬9 variant was predominantly in the nucleus (narrow arrows) and the GSK-3␤ Y216F variant was found in the cytoplasm (wide arrows). In A103, V28, and LNCaP cells that express AR, the AR (blue) was almost exclusively in the nucleus of R1881-treated cells. The distribution of GSK-3␤ (green) protein in cells that express AR (A103, V28, and LNCaP) was the same as cells that do not express AR (C3).
C3, or ARϩ cells derived from an ARϪ lineage, i.e. A103 and V28 cells (top row). The relative density represents the mean pixel density of the (P)Ser 9 -GSK-3␤ normalized to that of the total GSK-3␤. B, this diagram shows the structure of HA-tagged GSK-3␤ and mutants used in this study. 1, GSK-3␤wt contains an enzymatic site and two critical regulatory phosphorylation sites Ser 9 and Tyr
216
.
2, GSK-3␤
⌬9 is a deletion mutant that has the first 9 amino acids removed and is constitutively active because it is missing Ser 9 , the inhibitory phosphorylation site for Akt.
3, GSK-3␤
Y216F is an enzymatically inactive point mutant that has an essential tyrosine phosphorylation site mutated to a phenylalanine.
4, GSK-3␤
K85M is an enzymatically suppressed point mutant that has an essential lysine mutated to a methionine. C, GSK-3␤ variants are expressed in ARϩ cells. Only endogenous GSK-3␤ is expressed in the PCMV 4 vector control samples (lanes 1, 5, and 9). In general, the HA tag on these GSK-3␤ variants caused them to migrate above the endogenous GSK-3␤. GSK-3␤wt (lanes 2, 6, and 10) has migrated above the endogenous GSK-3␤. Constitutively active GSK-3␤ ⌬9 (lanes 3, 7, and 11) has migrated above and below the endogenous GSK-3␤. The inactive point mutant GSK-3␤ Y216F (lanes 4, 8, and 12) has migrated above the endogenous GSK-3␤. Heavy phosphorylation of Ser 9 occurs primarily on the endogenous GSK-3␤ in the presence of all variant proteins. Relative density represents the mean pixel density of the (P)Ser 9 -GSK-3␤ normalized to that of the total GSK-3␤. D, enzymatically active GSK-3␤ variants phosphorylate AR. Overexpression of constitutively active GSK-3␤ ⌬9 (lanes 3, 8, and 13) in ARϩ cell lines increased the phosphorylation of AR to its greatest extent, followed by the phosphorylation produced by GSK-3␤wt (lanes 2, 7, and 12). Vector controls (PCMV 4 , lanes 1, 6, and 11) and inactive GSK-3␤ Y216F (lanes 4, 9, and 14) point mutant-expressing cells showed less phosphorylation of AR, whereas treatment with GSK-3␤ inhibitor LiCl (2.0 mM, lanes 5, 10, and 15) actively suppressed the phosphorylation of AR. Relative density represents the mean pixel density of the 32 P-labeled AR normalized to that of the total AR. teracts with and is phosphorylated by GSK-3␤; and 3) examine the intracellular co-distribution of AR with mutated forms of GSK-3␤.
GSK-3␤ Inhibits AR Function

EXPERIMENTAL PROCEDURES
Cells and Culture Conditions-The human prostate adenocarcinoma cells PC-3, DU145, LNCaP, as well as COS-1 cells, were obtained from the American Tissue Type Culture Collection (Manassas, VA). PC-3 cells were selected that stably expressed empty pcDNA 3.1 vector (C3 cells), hAR/pcDNA 3.1 plasmid (A103 cells), or VP16-AR (V28 cells). All tumor cells were maintained in Dulbecco's modified Eagle's medium and F-12 medium (mixed 1:1) supplemented with 10% fetal bovine serum.
Western Blot Analysis-Western blot analysis was performed to detect various proteins in human prostate cancer cells. Whole cell lysates were prepared as previously described (22) . Proteins were then separated by SDS-PAGE, electrotransferred to nitrocellulose, and analyzed by chemiluminescence procedures, as previously described (22) .
GSK-3␤ Phosphorylation of AR in Cells-Various GSK-3␤ constructs were transfected into cells using FuGENE 6 (Roche Applied Science) according to the manufacturer's instructions. Cells were washed with phosphate free Dulbecco's modified Eagle's medium (Invitrogen) and then incubated with 0.5 mCi/ml [ 32 P]orthophosphate (Amersham Biosciences) in the presence of 1 nM 17␣-methyl-17␤-hydroxyestra-4,9,11-trien-3-one (R1881, otherwise known as metribolone, a synthetic nonmetabolizable androgen) for 6 h at 37°C (23) (24) (25) (26) . Radiolabeled medium was removed and cells were washed 3 times with cold phosphatebuffered saline and then scrape-harvested as previously described (22) . Immunoprecipitation studies were performed on 200 g of total protein using rabbit anti-AR antibody (Santa Cruz Biotechnology, Santa Cruz, CA), after which the proteins were examined by SDS-PAGE, electrotransferred to nitrocellulose, and subjected to autoradiography performed to detect 32 P-labeled AR. Electrotransferred proteins were probed with rabbit anti-AR polyclonal or mouse anti-AR monoclonal primary antibody (Santa Cruz Biotechnology) and visualized using the Super-Signal chemiluminescence substrate (Pierce).
Co-immunoprecipitation Assays-After starvation prostate cells were incubated with 1 nM R1881 for 20 min. Following treatment, cells were harvested and 200 g of total protein lysate was assayed by immunoprecipitation/Western blot analysis with either an N-or Cterminal specific AR binding antibody or GSK-3␤ specific antibody (Santa Cruz Biotechnology). Briefly, protein lysates were precleared by incubating with protein A/G-agarose (Pierce) for 30 min at 25°C. Specific antibodies (10 g/ml) were added to lysates and incubated for 16 h at 4°C, followed by washing 3 times with HEPES-buffered saline. Proteins that were bound to protein A/G were removed using SDS sample buffer and resolved by SDS-PAGE. Samples were then electrotransferred to nitrocellulose and probed with the reciprocal antibody overnight at 4°C. Immune complexes were visualized with West Femto chemiluminescence kit (Pierce).
Kinase Assays-pRSET-GST-ARLBD protein was produced in Escherichia coli and purified using the B-PER/GST Spin Purification Kit (Pierce) in the presence of 1 nM R1881. Purified GST-ARLBD was incubated with various concentrations of GSK-3␤ (New England Biolabs) in the presence of [␥-32 P]ATP (Amersham Biosciences) and analyzed by NuPage gradient gel electrophoresis (Invitrogen) followed by autoradiography.
Immunofluorescence Analysis-Immunofluorescence analysis was performed as described previously (22) . A primary rabbit polyclonal antibody recognizing GSK-3␤ (Santa Cruz) or mouse monoclonal antibody recognizing AR (BD Biosciences) was diluted (1:200; v/v) in buffer as previously described (22) . The samples were then incubated with an anti-rabbit secondary antibody Alexa-488 (green), an anti-mouse secondary antibody Alexa-350 (blue), and actin probe Alexa-594 phalloidin (red) (Molecular Probes), after which they were examined as previously described (22) .
Luciferase Assays-Transfection experiments were performed in triplicate using FuGENE 6. In one set of experiments, various AR constructs (ARwt, AR5, AR65, AR104, AR106, and AR126), previously
FIG. 4. Activated GSK-3␤ suppresses AR-mediated transcription.
A, increasing levels of GSK-3␤wt plasmid (0.03, 0.1, and 0.3 g) inhibited ARwt-driven (0.3 g) transcriptional activity in the presence of 1 nM R1881 as measured by ARE 2 -luciferase reporter (normalized to Renilla luciferase). The vector control (VC) was pCMV4. Lithium chloride (LiCl, 2.0 mM), a GSK-3␤ inhibitor, was used to eliminate GSK-3␤-induced suppression of AR transcriptional activity. Shown is the percentage of luciferase activity Ϯ S.E. data relative to the mean of samples treated with R1881 in the presence of ARwt (sixth column from the left) taken from two independent experiments involving 6 samples per condition. B, deletion mutants and point mutants of GSK-3␤ were used to determine their effect on ARwt-mediated PB-LUC reporter activity (normalized to Renilla luciferase). GSK-3␤wt and GSK-3␤
⌬9
suppressed ARwt-mediated PB-LUC transcriptional activity in the presence of R1881. The vector control and inactive point mutant GSK-3␤ Y216F had no effect on ARwt-mediated PB-LUC reporter activity in the absence or presence of ligand. Shown is the percentage of luciferase activity Ϯ S.E. data relative to the mean of samples treated with R1881 in the presence of ARwt (fifth column from the left) taken from two independent experiments involving 6 samples per condition. migrated above the endogenous GSK-3␤. The endogenous GSK-3␤ was phosphorylated on Ser 9 , but the variant GSK-3␤ proteins were not. Relative density represents the mean pixel density of the (P)Ser 9 -GSK-3␤ normalized to that of the total GSK-3␤. C, AR (blue) was observed in the nuclei (narrow arrows) of R1881-treated COS-1 cells that were co-transfected with AR and GSK-3␤ variants. The pattern of GSK-3␤ (green) expression in COS-1 cells was the same as that in the cancer cells. AR was present in the cell nuclei with GSK-3␤wt and GSK-3␤
⌬9 , but only the AR was observed in the nuclei (narrow arrows) of cells transfected with GSK-3␤ 2 and 3) dose dependently suppressed the phosphorylation of AR. Relative density represents the mean pixel density of the 32 P-labeled AR normalized to that of the total AR.
FIG. 5. GSK-3␤ phosphorylates the AR ligand-binding domain.
A, this diagram shows the AR structure, deletion mutants, and a point mutant used in this study. 1, ARwt domains include multiple activation domains (AD) in the N-terminal portion, a DNA-binding domain (DBD), a hinge region, and a ligand-binding domain (LBD) in the C-terminal portion of the molecule. 2, AR5 has the complete N-terminal portion and DBD, whereas the hinge and LBD are removed. 3, AR106 has only a single essential AD and the DBD present, causing it to be constitutively activated (see also Jenster et al. (28) ). 4, AR104 has the DBD, hinge, and LBD present but cannot activate transcription. 5, AR126 has the AD removed from the N-terminal portion and the DBD but no hinge or LBD, making it transcriptionally inactive. B, deletion mutants and point mutants of the AR were used to determine the AR protein domains that interacted with GSK-3␤ in the presence of R1881. AR5 is an N-terminal domain mutant, and AR104 is a C-terminal domain mutant both of which co-immunoprecipitated with GSK-3␤. N-terminal-specific and C-terminal-specific antibodies were immunoprecipitated with the appropriate domains of AR5 and AR104, respectively. C, in reciprocal studies using anti-GSK-3␤ antibody, described (27, 28) were transfected in combination with wild-type GSK-3␤ (GSK-3␤wt) (Fig. 5A) . In another set of experiments, various GSK-3␤ constructs previously described (29) (GSK-3␤wt, GSK-3␤ ⌬9 , GSK-3␤ K85M , and GSK-3␤
Y216F
) were transfected in combination with ARwt into COS-1 cells. Probasin-luciferase (PB-LUC) and pARE-LUC were the reporter constructs used to analyze AR-driven transcriptional activity. Cells were harvested and analyzed using the LUCLITE system (Packard Instrument Co.) and then quantitated in a 96-well black plate using a TOPCOUNT NT multiwell plate scintillation detector (Packard Instrument Co.). All results from the luciferase assays were normalized to Renilla luciferase activity, which was generated from pRLTK (Promega Corp.).
Immunostaining of Paraffin Sections-Immunohistochemistry was carried out in paraffin-embedded sections (3-4 m) following deparaffinization and rehydration in xylene, graded alcohol, and distilled H 2 O (DH 2 O), respectively. Antigen retrieval was performed in citrate buffer, pH 6.0, in steam. The endogenous peroxidase activity was quenched by incubating the sections in 3% hydrogen peroxide for 10 min at room temperature. After blocking the sections with avidin block followed by biotin block for 15 min each (Biogenex, San Ramon, CA) and then rinsing three times between treatments with phosphate-buffered saline, protein nonspecific blocking solution (Dako Corp., Carpinteria, CA) was applied and incubated for 20 min and slides were rinsed three times with phosphate-buffered saline. Rabbit anti-human GSK-3␤ (Cell Signaling Technology, Inc.) or AR antibodies (Santa Cruz Biotechnology, Inc.) diluted 1:50 with background reducing diluent (Dako Corp.) were applied to the sections and incubated overnight at 25°C. Then, the sections were incubated with the appropriate biotinylated secondary antibody and horseradish peroxidase-streptavidin (Dako Corp.) and rinsed three times with phosphate-buffered saline between steps. Peroxidase activity was detected by applying 3,3Ј-diaminobenzidine tetrahydrochloride containing 0.02% hydrogen peroxide for 10 min. The sections were counterstained with hematoxylin, rinsed with DH 2 O, intensified with a saturated lithium carbonate as a bluing agent, and rinsed again with DH 2 O. The sections were then dehydrated in graded alcohols, cleared in xylene, and mounted in Permount (Fisher) and covered with coverslips.
Image Analysis-Digital capture methods were optimized to provide the best signal-to-noise contrast for image analysis. We used a Quantix CCD camera that is driven by IP Labs (Scanalytics Inc., Fairfax, VA) image analysis software on a Power PC G4 computer with 128 megabytes of RAM. This image-acquisition equipment is attached to an IX70 inverted research light microscope (Olympus America Inc., Melville, NY).
RESULTS
Low GSK-3␤ Activity in Proliferating Prostate Cancer Cells-
We used Western blots to analyze GSK-3␤ protein expression and phosphorylation in proliferating prostate cells. The total levels of GSK-3␤ protein expression were similar in all the prostate cancer cells with little variation in phosphorylation at Tyr 216 (a constitutive phosphorylation event that activates this enzyme). In contrast, phosphorylation at Ser 9 suppressed GSK-3␤ activity and was very high in the androgen-dependent LNCaP prostate cancer cells (Fig. 1A, lanes 2 and 4) but lower in the androgen-independent PC-3 and DU145 prostate cancer cells (Fig. 1A, lanes 1 and 3) . Previously we verified that GSK-3␤ enzymatic activity inversely correlates with (P)-Ser 9 -GSK-3␤ levels in these prostate cancer cells. 2 To determine the effect of an androgen-independent cell background on AR activity, we selected PC-3 cells that stably express AR from a PC-3 cell background. When we selected PC-3 prostate cells that stably expressed a control vector (C3 cells), AR plasmid (A103 cells) or VP16-AR (V28 cells), Ser 9 did not increase to the same levels in these cells as observed in the androgen-expressing LNCaP cells (Fig. 1A, lanes 4 -7) .
Phosphorylation of GSK-3␤ Variants in AR-expressing Cells-We next overexpressed HA-tagged GSK-3␤ variants (29) (Fig. 1B) containing various point mutations or deletions in the AR-expressing LNCaP, A103, and V28 cells to determine how these molecular changes affected GSK-3␤ expression (Fig.  1C) . Deletion of the first 9 amino acids of GSK-3␤ resulted in the formation of the GSK-3␤
⌬9 protein, which is constitutively active and cannot be inactivated by Akt. Ser 9 phosphorylation was present on endogenous GSK-3␤ but not to the same degree on the transfected HA-tagged variants (Fig. 1C) . The position of the HA-tagged variants was verified using an anti-HA antibody. 3 
Prevention of GSK-3␤-induced Phosphorylation of AR by
LiCl-The phosphorylation of AR increased above that in control cells in the presence of GSK-3␤wt (Fig. 1D, lanes 2, 7, and  12) and to a greater extent in the presence of constitutively active GSK-3␤ ⌬9 (Fig. 1D, lanes 3, 8, and 13) . In contrast, the phosphorylation of AR was limited in the presence of PCMV 4 ( Fig. 1D, lanes 1, 6, and 11 ) and inactive GSK-3␤ Y216F (Fig. 1D,  lanes 4, 9, and 14) . Phosphorylation was further decreased in cells treated with 2.0 mM lithium chloride (LiCl), a GSK-3␤ inhibitor (Fig. 1D, lanes 5, 10, and 15) . These data suggest that GSK-3␤ is involved in phosphorylating AR.
Distribution of GSK-3␤ Variants and AR in Cell Nuclei-We examined the intracellular distribution of the different GSK-3␤
(green) proteins, the AR (blue) and actin (red) in immunofluorescence studies to determine whether these molecules could interact within cells (Fig. 2) . Untransfected PC-3 and C3 cells contained low levels of endogenous GSK-3␤ that were located in both the cytoplasm and nucleus of the PC-3 cells. Overexpressed GSK-3␤wt was also present in both the cytoplasm and nucleus of transfected cells. However, the GSK-3␤ Y216F protein was predominantly found in the cytoplasm, and the GSK-3␤
⌬9
protein was predominantly found in the nucleus of transfected cells. In addition, AR was not present in the PC3-C3 control cells that expressed the empty vector but was present in the nuclei of all R1881-treated AR-expressing cells. In the absence of R1881 by contrast, much less AR was found in the nuclei of AR-expressing cells (data not shown). These data show that the intracellular distribution of both AR and GSK-3␤ did not influence each other. AR was predominantly in the nuclei of R1881-treated prostate cells and was not affected by the distribution of GSK-3␤. In contrast, the intracellular distribution of GSK-3␤ appears to rely in part on its phosphorylation status, in particular, the absence of the Tyr 216 phosphorylation site prevented the distribution of GSK-3␤ Y216F into cell nuclei. These data suggest that although the intracellular distribution of AR and GSK-3␤ do not depend on each other, these two molecules are capable of co-localizing in cancer cell nuclei, which would enable GSK-3␤ to phosphorylate AR.
ARwt co-immunoprecipitated with endogenous GSK-3␤ in vector-transfected cells and with GSK-3␤wt when expressed in transfected cells. Immunoprecipitation experiments were performed twice and gave similar results. D, phosphorylation of AR deletion mutants occurs in intact cells. The phosphorylation of AR5 and AR104 was low in vector-transfected cells. The phosphorylation of AR5 increased slightly and the phosphorylation of AR104 increased greatly when co-transfected with GSK-3␤
⌬9 . E, in vitro kinase assays revealed that increasing levels of purified GSK-3␤ (1 and 5 units) can dose-dependently phosphorylate purified GST-ARLBD (1 g/lane) in the presence of [␥-32 P]ATP. F, GSK-3␤wt plasmid (0.3 g) inhibited ARwt-induced PB-LUC reporter activity in the presence of 1 nM R1881 by ϳ50%. AR5, a deletion mutant that contained the entire N terminus and the DBD but no hinge LBD and AR106, a deletion mutant that contained only the essential N-terminal activation domain, could not be effectively suppressed by GSK-3␤wt either in the absence or presence of R1881. Little PB-LUC signal was observed when AR104 or AR126 were transfected into cells. Shown is the percentage of luciferase activity Ϯ S.E. data relative to the mean of samples treated with R1881 in the presence of ARwt (third column from the left) taken from two independent experiments involving 6 samples per condition.
Low GSK-3␤ Activity in COS-1 Cells-We used COS-1 cells to characterize the interactions between GSK-3␤ and AR deletion variants because they are easy to transfect and do not express endogenous AR. First, however, we determined that the expression pattern and phosphorylation status of GSK-3␤ were similar to those in the LNCaP cells, in that Ser 9 was phosphorylated (Fig. 3A) and the kinase activity was low (data not shown). Similar to prostate cancer cells, when we expressed GSK-3␤ variants in COS-1 cells, the endogenous GSK-3␤ was phosphorylated on Ser 9 , but was decreased in the GSK-3␤ variants (Fig. 3B) .
Distribution of GSK-3␤ Variants and AR in COS-1 CellsWe examined the intracellular distribution of the different GSK-3␤ (green) proteins and the AR (blue) and actin (red) using immunofluorescence analysis (Fig. 3C) . The intracellular distribution of each mutant form was similar to prostate cancer cells. Both GSK-3␤wt and constitutively active GSK-3␤
⌬9 , but not the GSK-3␤ Y216F variant, were present with AR in cell nuclei.
Enhancement of Phosphorylation of AR by Enzymatically Active GSK-3␤ Variants and LY294002-The co-transfection of AR with GSK-3␤wt or GSK-3␤
⌬9 elevated the phosphorylation of AR in COS-1 cells (Fig. 3D, lanes 3 and 4) , whereas the co-expression of AR with PCMV 4 or GSK-3␤ Y216F or GSK-3␤ K85M did not (Fig. 3D, lanes 1, 6, and 7) . The treatment of cells with the phosphatidylinositol 3-kinase-specific inhibitor LY294002 (20 M) enhanced the phosphorylation of AR by endogenous GSK-3␤ in the presence of the empty PCMV 4 vector or GSK-3␤ ⌬9 (Fig. 3D, lanes 2 and 5) . This is because of LY294002 effects on endogenous GSK-3␤, which when combined with GSK-3␤ ⌬9 further elevates the phosphorylation of AR. In contrast, the addition of LiCl in the presence of GSK3␤wt dose-dependently inhibited its ability to phosphorylate AR (Fig. 3E, lanes 2 and 3) . These data illustrate that by manipulating GSK-3␤ activation through genetic or pharmacologic methods, once activated GSK-3␤ can phosphorylate AR.
Dose-dependent Inhibition of ARE Driven Transcription by GSK-3␤-The
ARwt was co-transfected with GSK-3␤wt at the indicated concentrations or in combination with 0.3 g of the empty vector control in COS-1 cells (Fig. 4A) . In the presence of 1 nM R1881, a high affinity synthetic nonmetabolizable androgen (23) (24) (25) 30) , ARE 2 LUC reporter activity decreased as the GSK-3␤wt concentration increased. Conversely, treatment with 10 mM LiCl relieved the inhibition of AR-mediated transcription produced by GSK-3␤.
Inhibition of AR-mediated Transcription by GSK-3␤-GSK-3␤ variants were co-transfected with ARwt in COS-1 cells to determine their effects on AR driven PB-LUC transcription. In contrast to the ARE 2 LUC promoter mentioned above (Fig.  4A) , the PB promoter is a complex promoter from a known endogenous AR target gene (Fig. 4B) . GSK-3␤wt and GSK-3␤ ⌬9 substantially inhibited ARwt-mediated PB-LUC transcription in the presence of 1 nM R1881 (Fig. 4B) . In contrast, the catalytically inactive GSK-3␤ Y216F construct (Fig. 4B ) and the GSK-3␤ K85M (data not shown) did not suppress AR-mediated transcription either in the absence or presence of R1881.
Protein-Protein Interactions between GSK-3␤ and AR-AR mutants containing the various protein domains of the AR were expressed in COS-1 cells in the presence of 1 nM R1881 (Fig. 5,  A-C) . When we used antibodies that recognized either the N-or C-terminal domains of AR to immunoprecipitate AR complexes, the appropriate deletion mutant, either AR5 or AR104, respectively, was immunoprecipitated along with the GSK-3␤ (Fig.  5B) . These antibodies could also co-immunoprecipitate ARwt along with GSK-3␤ (Fig. 5B) . In reciprocal immunoprecipitation experiments we used the anti-GSK-3␤ antibody to coimmunoprecipitate either endogenous GSK-3␤ or GSK-3␤wt along with the exogenous AR (Fig. 5C) .
Phosphorylation of N-and C-terminal AR Domain Mutants by Constitutively
Active GSK-3␤⌬9 -The phosphorylation of both N-(AR5) and C-terminal (AR104) domain AR mutants was minimal in the presence of empty PCMV 4 vector but was increased in the presence of GSK-3␤ ⌬9 (Fig. 5D) . However, the phosphorylation of the C-terminal domain (AR104) was greater than that of the N-terminal domain (AR5). The C-terminal domain contains at least 3 highly likely consensus sites for phosphorylation by GSK-3␤. 3 In Vitro Phosphorylation of GST-ARLBD Protein by GSK-3␤-Recombinant GST-ARLBD protein was phosphorylated in vitro by purified GSK-3␤ in the presence of [␥-32 P]ATP (Fig.  5E ). The phosphorylation of 1 g of GST-ARLBD increased as the GSK-3␤ enzyme concentration increased suggesting that the ARLBD can serve as a substrate for GSK-3␤ enzyme activity.
Regulation of the Transcriptional Activity of AR Deletion Mutants by GSK-3␤-We transfected various AR deletion constructs either alone or with GSK-3␤wt into COS-1 cells to determine which domains of AR interacted with GSK-3␤ to elicit inhibition. When the ARwt were co-transfected with GSK-3␤wt, PB-LUC transcription decreased by ϳ50% in the presence of R1881 (Fig. 5F ). In contrast, AR5, which lacks the hinge region and ligand-binding domain, was not inhibited by GSK-3␤ co-expression. Similarly, the constitutively active AR106 also resisted GSK-3␤ regulation. These data are consistent with previous findings that showed AR5 and AR106 act as constitutively activated transcription factors that do not require ligand binding to activate transcription (Fig. 5F) (28) . In contrast, the AR104 and AR126 constructs that contain a DNA-binding domain but lack an activation domain did not support any significant transcriptional activity (Fig. 5F) (28) . These data suggest that the complete AR molecule, which includes both the activation domain DNA-binding domain and the ligand-binding domain, is important for the regulation of AR-driven transcriptional activity by GSK-3␤.
GSK-3␤ and AR Co-distribute in Prostate Cancer TissueImmunohistochemical staining of prostate cancer tissue samples showed that GSK-3␤ and AR were diffusely distributed in the cytoplasm or concentrated in the nuclei (arrows) of prostate cancer cells (Fig. 6) . The co-distribution of GSK-3␤ and AR in prostate cancer tissue suggests that these molecules are capable of interacting in both the cytoplasmic or nuclear compartments of prostate cancer cells.
DISCUSSION
To determine whether Akt indirectly regulates AR through GSK-3␤, we examined the ability of GSK-3␤ to phosphorylate AR in intact cells. First, we bypassed Akt by using a constitutively active GSK-3␤
⌬9 that cannot be inactivated by Akt. GSK-3␤
⌬9 phosphorylated AR in LNCaP, A103, and V28 prostate carcinoma cells that stably expressed the receptor (Fig. 1D ) and in COS-1 cells that transiently expressed AR (Fig. 3D) . The phosphorylation of AR increased by using an indirect inhibitor of Akt (LY294002, a phosphatidylinositol 3-kinase inhibitor, Fig. 3D, lane 2) , which we previously showed to increase endogenous GSK-3␤ activity in prostate carcinoma cells (21) . Furthermore, AR phosphorylation reached its highest level in the cells that expressed constitutively active GSK-3␤
⌬9 that were also treated with LY294002 to inhibit endogenous GSK-3␤ activity (Fig. 3D, lane 5) . In addition, LiCl, a GSK-3␤ inhibitor, significantly inhibited the phosphorylation of AR in prostate cancer cells (Fig. 1D, lanes 5, 10, and 15 ) and in the COS-1 cells (Fig. 3E) . These findings show that phosphorylation of AR involves GSK-3␤ activity in cells when Akt is bypassed using mutant GSK-3␤ ⌬9 or Akt is inhibited by a phosphatidylinositol 3-kinase inhibitor.
GSK-3␤ is able to regulate many signaling pathways because it possesses unique structural characteristics that cause it to recognize prephosphorylated substrates (19, 20, (31) (32) (33) . Importantly, the catalytic efficiency of GSK-3␤ for a phospho-substrate is increased to 400 -1000-fold in prephosphorylated as opposed to unphosphorylated substrates (20) . Computer analysis has revealed the AR has at least 15 consensus sites, (S/ T)XXX(S/T)PO 4 (S/T, serine/threonine; X, any residue; PO 4 , downstream prephosphorylation) that GSK-3␤ can phosphorylate. 3 Three of these consensus sites were found in the hingeligand binding domains of AR corresponding to the segment of the molecule that we showed was phosphorylated when GSK-3␤ was activated both in vivo and in vitro. At least 3 putative prephosphorylation consensus sites were observed to be phosphorylated by Gioeli et al. (18) , but they did not observe phosphorylation by GSK-3␤, likely because it is greatly suppressed by Akt in the LNCaP cells they used in this study.
Although GSK-3␤ has numerous substrates in both the nucleus and cytoplasm (19) , there is little information on the mechanisms that mediate its intracellular distribution. We found that eliminating the first 9 amino acids in the HA-tagged ⌬9 mutant of GSK-3␤ caused this variant to accumulate in the nucleus, which co-distributed with AR (Figs. 2 and 3C ). This accumulation of GSK-3␤ ⌬9 was associated with the suppression of AR-mediated transcription. When Tyr 216 on GSK-3␤ was converted to phenylalanine in the point mutant GSK-3␤ Y216F , this limited the accumulation of this variant in the cell nucleus (Figs. 2 and 3C ), which in part prevents this variants ability to suppress AR activity (Figs. 2 and 3C ). As part of this ongoing study, we have also examined paraffin-embedded tissue sections from prostate cancer patients using immunohistochemical analysis and found that AR and GSK-3␤ are capable of co-distributing in the nuclei of cancer cells (Fig. 6) suggesting that these two molecules may interact during the progression of prostate cancer.
We were also able to co-immunoprecipitate AR and GSK-3␤, suggesting that there was a physical interaction between them. However, we did not determine what regions of GSK-3␤ bind to the AR. Nevertheless, a number of putative GSK-3␤ consensus sites are present in the hinge region and surrounding the ligand-binding pocket of AR, 3 which may help regulate AR. In some experiments GSK-3␤wt or constitutively active GSK-3␤
⌬9
showed inhibition of ARwt-driven reporter activity in the absence of R1881 ligand (Fig. 4, A and B) , but in others this inhibition was not as great (Fig. 5F ). Whether ligand binding may affect GSK-3␤wt-mediated regulation of AR function will require further study.
Our finding that GSK-3␤ inhibits AR activity may help explain AR activity in prostate cancer cells. The inactivation of GSK-3␤ by Akt and subsequent relief of this inhibition may also affect lose androgen sensitivity/dependence of prostate tumor cells after androgen ablation therapy. The resultant kinase-mediated phosphorylation of AR can influence many functions, including nuclear translocation, DNA binding, interaction with regulatory proteins (1), and, as suggested in this study, inhibition of the AR by phosphorylating the hinge and/or ligand-binding domain. Further understanding of how GSK-3␤ influences AR function and the molecular target sites involved will undoubtedly elucidate how androgen-dependent prostate cancer is transformed into androgen-independent prostate cancer after androgen ablation therapy.
